Systems medicine paves the way for improved treatment for leukemia patients

A new individualised systems medicine strategy enables a selection of potentially effective cancer therapies for individual patients. The promising results achieved by applying this strategy to chemoresistant adult acute myeloid leukaemia patients have been recently published
A multi-disciplinary team of researchers at the Institute for Molecular Medicine Finland, FIMM, and the Helsinki University Central Hospital has developed a novel individualised systems medicine (ISM) strategy which enables selection of potentially effective cancer therapies for individual patients.
Results achieved by applying this strategy to 28 patient samples have been recently published.
Most of the patients studied had chemoresistant adult acute myeloid leukaemia (AML), a disease characterised by poor prognosis.
AML is today largely treated by the same chemotherapeutic agents as applied 30-50 years ago. Here, the researchers measured the response of patients